Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.76 |
| ▸ | TGFBR2 | P37173 | 5/20 | 0.76 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554210 | 0.89 | TGFBR1 (0.64) | TGFBR1TGFBR2 | |
| SCHEMBL18554245 | 0.89 | TGFBR1 (0.76) | TGFBR1TGFBR2 | |
| SCHEMBL18456541 | 0.86 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18554243 | 0.85 | TGFBR1 (0.65) | TGFBR1TGFBR2 | |
| SCHEMBL18554269 | 0.84 | TGFBR1 (0.66) | TGFBR1TGFBR2 | |
| SCHEMBL18554165 | 0.83 | TGFBR1 (0.67) | TGFBR1TGFBR2 | |
| SCHEMBL18397440 | 0.79 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18554130 | 0.77 | TGFBR1 (0.66) | TGFBR1TGFBR2 | |
| SCHEMBL18554301 | 0.77 | TGFBR1 (0.73) | TGFBR1TGFBR2 | |
| SCHEMBL18554355 | 0.76 | TGFBR1 (0.75) | TGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180250303-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-06 | — | — | US | claimed |
| EP-3341372-A1 | TGF BETA RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2018-07-04 | — | — | EP | claimed |
| WO-2017035118-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-02 | — | — | WO | claimed |
| US-20180250303-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-06 | — | — | US | disclosed |
| EP-3341372-A1 | TGF BETA RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017035118-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017035118-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250303-A1 | TGF BETA RECEPTOR ANTAGONISTS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885TGFBR2 2/4885BRAF 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.